Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Jenna Peters

Nurse Practitioner Knoxville, TN Nurse Practitioner

NPI 1447039748 CMS profile 11540753

10820 Parkside Dr, Knoxville, TN 37934

Open in the dashboard

General payments

$2,338

101 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenna Peters of Knoxville, TN is reported in the CMS Open Payments database as having received $2,338 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,430 63
2024 General $908 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenna Peters
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jenna Peters were reported at $1,430. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jenna Peters Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $908 $173 $55–$556 $164
2025 $1,430 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Avadel CNS Pharmaceuticals, LLC $447 17 payments
  2. Axsome Therapeutics, Inc. $431 17 payments
  3. Inspire Medical Systems, Inc. $430 13 payments
  4. Harmony Biosciences LLC $398 28 payments
  5. Jazz Pharmaceuticals Inc. $342 11 payments
  6. Respicardia, Inc. $177 9 payments
  7. Lilly USA, LLC $64 4 payments
  8. Fisher & Paykel Healthcare Inc $27 1 payment
  9. 3B Medical, Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $2,191 99 payments
  2. Education $147 2 payments
Products named General payments · program years 2024–2025
  1. LUMRYZ $447 17 payments
  2. Sunosi $431 17 payments
  3. INSPIRE $430 13 payments
  4. XYWAV $342 11 payments
  5. WAKIX Narcolepsy $240 17 payments
  6. remede System $177 9 payments
  7. WAKIX Narcoplepsy $158 11 payments
  8. ZEPBOUND $64 4 payments
  9. FISHER & PAYKEL HEALTHCARE Sleep $27 1 payment
  10. FISHER & PAYKEL HEALTHCARE Sleep $27 1 payment
  11. Other $103 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

464

Median for Nurse Practitioner: 389

Drug cost

$5,243

Median for Nurse Practitioner: $21,885

Branded share of claims

4.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 209 $2,557
Modafinil Generic 12 $543
Armodafinil Generic 13 $447
Doxepin Hcl Generic 26 $340
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 11 $326
Clonazepam Generic 50 $237
Zolpidem Tartrate Generic 63 $192
Trazodone Hcl Generic 34 $171
Mirtazapine Generic 12 $156
Hydroxyzine Hcl Generic 11 $111

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$28,262

Medicare's payments for the services billed

Medicare patients

350

Average age 73

Services billed

508

157 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 43%
Ischemic heart disease 35%
Chronic kidney disease 33%
Depression 32%
Atrial fibrillation 29%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LUMRYZ
  • Avadel CNS Pharmaceuticals, LLC $257
$257 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $242
$242 — —
WAKIX
  • Harmony Biosciences LLC $158
$158 — —
Sunosi
  • Axsome Therapeutics, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record